| Business Summary | | Onyx
Pharmaceuticals,
Inc.
is
developing
products
for
the
treatment
of
cancer.
Based
on
its
proprietary
virus
technology,
the
Company
is
developing
its
lead
product,
CI-1042.
CI-1042
is
a
human
virus
genetically
engineered
to
selectively
replicate
in
and
kill
cancer
cells
based
on
the
mutation
or
loss
of
function
of
a
specific
tumor-suppressor
gene,
the
p53
gene.
The
Company
has
completed
two
Phase
II
clinical
trials
of
CI-1042,
and
based
on
the
data
from
these
trials,
it
has
initiated
a
300-patient,
multi-center
Phase
III
clinical
trial
of
CI-1042,
administered
by
direct
injection
into
tumors,
or
intratumoral
injection,
in
patients
with
head
and
neck
cancer.
This
Phase
III
clinical
trial
is
being
conducted
in
conjunction
with
Warner-Lambert
Company,
a
subsidiary
of
Pfizer,
Inc.,
its
collaborator
for
the
development
and
commercialization
of
CI-1042. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ONXX
is
engaged
in
the
discovery
and
development
of
novel
therapeutics,
including
both
small
molecule
drugs
and
therapeutic
viruses
based
upon
the
genetics
of
human
disease
with
an
emphasis
on
cancer.
For
the
six
months
ended
6/30/01,
revenues
fell
32%
to
$10.1
million.
Net
loss
totaled
$11.1
million,
up
from
$242
thousand.
Revenues
reflect
the
absence
of
the
payment
from
Warner-Lambert.
Higher
loss
also
reflects
increased
clinical
trial
and
contract
manufacturing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Hollings Renton, 53 Chairman,
Pres, CEO | $383K | Judith Blakemore, 51 Acting
COO | -- | Helen Kim, 37 Sr.
VP, Clinical Devel. | -- | Leonard Post Sr. VP, R&D | -- | Thomas Dubensky VP,
Virology | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|